.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
States have an important role in ensuring food safety and healthy food practices.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Subscribe To Our Newsletter & Stay Updated
